Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.

EphB4, a member of the largest family of receptor tyrosine kinases, is normally expressed on endothelial and neuronal cells. Although aberrant expression of EphB4 has been reported in several human tumors, including breast cancer, its functional significance is not understood. We report here that EphB4 is expressed in 7 of 12 (58%) human breast cancer specimens and 4 of 4 (100%) breast tumor cell lines examined. Overexpression of EphB4 in breast cancer cells was driven by gene amplification and by the erbB family of receptors via activation of Janus tyrosine kinase-signal transducers and activators of transcription and protein kinase B. The aberrantly expressed receptor was phosphorylated by its natural ligand, EphrinB2, and signaled via the protein kinase B pathway. Targeted knockdown of EphB4 expression by small interference RNA (and antisense oligodeoxynucleotides (ODNs)) led to dose-dependent reduction in cell survival, increased apoptosis, and sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Antisense ODN-mediated EphB4 knockdown resulted in reduced tumor growth in a murine tumor xenograft model. Antisense ODN-treated tumors were 72% smaller than control tumors at 6 weeks, with an 86% reduction in proliferating cells, 15-fold increase in apoptosis, and 44% reduction in tumor microvasculature. Our data indicate that biologically active EphB4 functions as a survival factor in breast cancer and is a novel target for therapy.

[1]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[2]  A. Tulpule,et al.  Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. , 2005, Blood.

[3]  Hai Hu,et al.  Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. , 2004, Cancer genetics and cytogenetics.

[4]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[5]  E. Pasquale,et al.  Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Suda,et al.  Ephrin-B2 Induces Migration of Endothelial Cells Through the Phosphatidylinositol-3 Kinase Pathway and Promotes Angiogenesis in Adult Vasculature , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[7]  C. Nobes,et al.  Rac-dependent trans-endocytosis of ephrinBs regulates Eph–ephrin contact repulsion , 2003, Nature Cell Biology.

[8]  M. Zimmer,et al.  EphB–ephrinB bi-directional endocytosis terminates adhesion allowing contact mediated repulsion , 2003, Nature Cell Biology.

[9]  Gudrun Dandekar,et al.  Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells , 2003, Journal of Cell Science.

[10]  P. Scalia,et al.  Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops , 2003, International journal of cancer.

[11]  L. Mazzucchelli,et al.  Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Guoyao Wu,et al.  Eph B4 Receptor Signaling Mediates Endothelial Cell Migration and Proliferation via the Phosphatidylinositol 3-Kinase Pathway* , 2002, The Journal of Biological Chemistry.

[13]  E. Dreher,et al.  Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. , 2002, Oncology reports.

[14]  A. Bell,et al.  A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. , 2002, Molecular cell.

[15]  P. Hewett,et al.  Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer , 2001, BMC Molecular Biology.

[16]  G Garcia-Cardena,et al.  Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. , 2001, Developmental biology.

[17]  E. Pasquale,et al.  Eph receptors and ephrin ligands: embryogenesis to tumorigenesis , 2000, Oncogene.

[18]  D. Anderson,et al.  Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. , 1999, Molecular cell.

[19]  C. Tickle,et al.  Epithelial cell movements and interactions in limb, neural crest and vasculature. , 1999, Current opinion in genetics & development.

[20]  R. Klein,et al.  Eph receptors and ephrins: effectors of morphogenesis. , 1999, Development.

[21]  M. Lackmann,et al.  An early developmental role for Eph-ephrin interaction during vertebrate gastrulation , 1999, Mechanisms of Development.

[22]  F. Diella,et al.  Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. , 1999, Genes & development.

[23]  David G Wilkinson,et al.  Eph receptors and ephrins in neural development , 1999, Current Opinion in Neurobiology.

[24]  David J. Anderson,et al.  Molecular Distinction and Angiogenic Interaction between Embryonic Arteries and Veins Revealed by ephrin-B2 and Its Receptor Eph-B4 , 1998, Cell.

[25]  E. Pasquale,et al.  The Eph family of receptors. , 1997, Current opinion in cell biology.

[26]  T. Pawson,et al.  Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands , 1996, Nature.

[27]  B. Gusterson,et al.  Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium. , 1996, Biochemical and biophysical research communications.

[28]  A. Andres,et al.  Protein tyrosine kinase expression during the estrous cycle and carcinogenesis of the mammary gland , 1995, International journal of cancer.

[29]  H Sugimura,et al.  Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. , 1994, Cancer research.

[30]  D. Goeddel,et al.  Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. , 1994, The Journal of biological chemistry.

[31]  I. Ellis,et al.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer. , 1991, British Journal of Cancer.

[32]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[33]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[34]  J. Nesland,et al.  Expression of Ephb2 and Ephb4 in breast carcinoma , 2008, Pathology & Oncology Research.

[35]  R. Walker,et al.  Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas , 2004, Breast Cancer Research and Treatment.

[36]  W. Gullick,et al.  The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer , 2004, Breast Cancer Research and Treatment.

[37]  A. Andres,et al.  Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. , 2002, Journal of cell science.